AbbVie Inc. - Product Pipeline Review - 2016

  • ID: 3691101
  • Company Profile
  • 204 pages
  • Global Markets Direct
  • AbbVie, Inc.
1 of 4
AbbVie Inc. - Product Pipeline Review - 2016

Summary

‘AbbVie Inc. - Product Pipeline Review - 2016’, provides an overview of the AbbVie Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by AbbVie Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of AbbVie Inc.
- The report provides overview of AbbVie Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses AbbVie Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features AbbVie Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate AbbVie Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for AbbVie Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding AbbVie Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables

List of Figures

AbbVie Inc. Snapshot

AbbVie Inc. Overview

Key Information

Key Facts

AbbVie Inc. - Research and Development Overview

Key Therapeutic Areas

AbbVie Inc. - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Combination Treatment Modalities

Pipeline Products - Partnered Products

Pipeline Products - Out-Licensed Products

AbbVie Inc. - Pipeline Products Glance

AbbVie Inc. - Late Stage Pipeline Products

AbbVie Inc. - Clinical Stage Pipeline Products

AbbVie Inc. - Early Stage Pipeline Products

AbbVie Inc. - Drug Profiles

adalimumab

daclizumab

elotuzumab

ibrutinib

venetoclax

Viekira-3QD

(ombitasvir + paritaprevir + ritonavir) + dasabuvir

atrasentan hydrochloride

elagolix sodium

fluvoxamine maleate

glecaprevir

glecaprevir + pibrentasvir

ombitasvir

paricalcitol

paritaprevir

pibrentasvir

upadacitinib tartrate

veliparib

depatuxizumab mafodotin

ABT-122

ABT-436

ABT-981

depatuxizumab

navitoclax dihydrochloride

ABBV-075

ABBV-084

ABBV-085

ABBV-221

ABBV-672

ABBV-838

ABBV-8E12

ABT-165

ABT-257

ABT-399

ABT-555

ABT-700

ABT-767

ABT-957

ilorasertib

A-1048400

A-1262543

A-1264087

A-431404

A-705253

A-889425

A-988315

ABT-207

ABT-737

APG-880

Biologics for Undisclosed Indication

h-5F9AM8

Monoclonal Antibodies to Inhibit RGMa for Multiple Sclerosis

Monoclonal Antibody Conjugates for Oncology

Small Molecule to Inhibit PKC Theta for Autoimmune Disease

Small Molecule to Inhibit WEE-1 for Oncology

Small Molecules to Antagonize GnRH for Endometriosis, Male Health, Uterine Fibroids and Oncology

SOL-1

A-893

Monoclonal Antibodies for Chronic Pain

Small Molecules to Inhibit CDPK1 for Protozoal Infections

Small Molecules to Inhibit Jak1 for Undisclosed Indication

Small Molecules to Inhibit MCL-1 for Cancer

AbbVie Inc. - Pipeline Analysis

AbbVie Inc. - Pipeline Products by Target

AbbVie Inc. - Pipeline Products by Route of Administration

AbbVie Inc. - Pipeline Products by Molecule Type

AbbVie Inc. - Pipeline Products by Mechanism of Action

AbbVie Inc. - Recent Pipeline Updates

AbbVie Inc. - Dormant Projects

AbbVie Inc. - Discontinued Pipeline Products

Discontinued Pipeline Product Profiles

AbbVie Inc. - Company Statement

AbbVie Inc. - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

AbbVie Inc., Key Information

AbbVie Inc., Key Facts

AbbVie Inc. - Pipeline by Indication, 2016

AbbVie Inc. - Pipeline by Stage of Development, 2016

AbbVie Inc. - Monotherapy Products in Pipeline, 2016

AbbVie Inc. - Combination Treatment Modalities in Pipeline, 2016

AbbVie Inc. - Partnered Products in Pipeline, 2016

AbbVie Inc. - Partnered Products/ Combination Treatment Modalities, 2016

AbbVie Inc. - Out-Licensed Products in Pipeline, 2016

AbbVie Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016

AbbVie Inc. - Pre-Registration, 2016

AbbVie Inc. - Filing rejected/Withdrawn, 2016

AbbVie Inc. - Phase III, 2016

AbbVie Inc. - Phase II, 2016

AbbVie Inc. - Phase I, 2016

AbbVie Inc. - Preclinical, 2016

AbbVie Inc. - Discovery, 2016

AbbVie Inc. - Pipeline by Target, 2016

AbbVie Inc. - Pipeline by Route of Administration, 2016

AbbVie Inc. - Pipeline by Molecule Type, 2016

AbbVie Inc. - Pipeline Products by Mechanism of Action, 2016

AbbVie Inc. - Recent Pipeline Updates, 2016

AbbVie Inc. - Dormant Developmental Projects,2016

AbbVie Inc. - Discontinued Pipeline Products, 2016

AbbVie Inc., Subsidiaries

List of Figures

AbbVie Inc. - Pipeline by Top 10 Indication, 2016

AbbVie Inc. - Pipeline by Stage of Development, 2016

AbbVie Inc. - Monotherapy Products in Pipeline, 2016

AbbVie Inc. - Partnered Products in Pipeline, 2016

AbbVie Inc. - Pipeline by Top 10 Target, 2016

AbbVie Inc. - Pipeline by Route of Administration, 2016

AbbVie Inc. - Pipeline by Molecule Type, 2016

AbbVie Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll